Po134 Analysis of Primary Breast Cancer (Bc) Expression of Programmed cell Death 1 (Pd-1) Receptor and Programmed Death Ligand 1 (Pd-L1) to Determine Associations with Clinical Characteristics and Outcomes
Vidula, N.; Yau, C.; Goga, A.; Rugo, H.S.
The Breast 24: S67-S68
2015
DOI: 10.1016/s0960-9776(15)30146-6
Accession: 067139222
PDF emailed within 0-6 h: $19.90
Related References
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61Chen, Z.; Hu, K.; Feng, L.; Su, R.; Lai, N.; Yang, Z.; Kang, S. 2018: Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer Cancer Science 109(6): 1753-1763
Ilie, M.; Juco, J.; Huang, L.; Hofman, V.; Khambata-Ford, S.; Hofman, P. 2018: Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients Cancer Cytopathology 126(4): 264-274
van Erp, A.E.M.; Versleijen-Jonkers, Y.M.H.; Hillebrandt-Roeffen, M.H.S.; van Houdt, L.; Gorris, M.A.J.; van Dam, L.S.; Mentzel, T.; Weidema, M.E.; Savci-Heijink, C.Dilara.; Desar, I.M.E.; Merks, H.H.M.; van Noesel, M.M.; Shipley, J.; van der Graaf, W.T.A.; Flucke, U.E.; Meyer-Wentrup, F.A.G. 2017: Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 + lymphocytes in primary sarcomas is subtype dependent Oncotarget 8(41): 71371-71384
Cortellini, A.; Bersanelli, M.; Santini, D.; Buti, S.; Tiseo, M.; Cannita, K.; Perrone, F.; Giusti, R.; De Tursi, M.; Zoratto, F.; Marconcini, R.; Russano, M.; Zeppola, T.; Anesi, C.; Filetti, M.; Marchetti, P.; Botticelli, A.; Gelibter, A.; De Galitiis, F.; Vitale, M.Giuseppa.; Rastelli, F.; Tudini, M.; Silva, R.Rita.; Atzori, F.; Chiari, R.; Ricciuti, B.; De Giglio, A.; Migliorino, M.Rita.; Mallardo, D.; Vanella, V.; Mosillo, C.; Bracarda, S.; Rinaldi, S.; Berardi, R.; Natoli, C.; Ficorella, C.; Porzio, G.; Ascierto, P.A. 2020: Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events European Journal of Cancer 128: 17-26
Ren, Y.; Lv, Q.; Yue, W.; Liu, B.; Zou, Z. 2020: The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases Melanoma Research 30(1): 85-101
Bari, S.; Muzaffar, J.; Chan, A.; Jain, S.R.; Haider, A.M.; Adams Curry, M.; Hostler, C.J. 2019: Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer Journal of Oncology 2019: 2989048
Grimm, M.; Gasser, M.; Koenigshausen, M.; Stein, C.; Lutz, J.; Krol, S.; Thiede, A.; Heemann, U.; Waaga-Gasser, A. 2016: Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer Journal of Clinical Oncology 26(15_Suppl): 15005-15005
Del C Monroig-Bosque, P.; Driver, B.; Morales-Rosado, J.A.; Deavers, M.; Tacha, D.; Bernicker, E.; Cagle, P.T.; Miller, R.A. 2018: Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma Archives of Pathology and Laboratory Medicine 142(11): 1388-1393
Zhang, Y.; Zhu, W.; Zhang, X.; Qu, Q.; Zhang, L. 2017: Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer Oncology Letters 14(6): 7225-7231
Ohigashi, Y.; Sho, M.; Yamada, Y.; Tsurui, Y.; Hamada, K.; Ikeda, N.; Mizuno, T.; Yoriki, R.; Kashizuka, H.; Yane, K.; Tsushima, F.; Otsuki, N.; Yagita, H.; Azuma, M.; Nakajima, Y. 2005: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(8): 2947-2953
Lazarus, G.; Audrey, J.; Iskandar, A.William.Brian. 2019: Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review Oncology Reviews 13(2): 425
Liu, Y.; Ma, J.; Yu, K.; Li, M.; Liu, F.; Yan, Q.; Wang, Z.; Guo, S. 2018: Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas Pathology Research and Practice 214(4): 507-512
Mikami, S.; Mizuno, R.; Kondo, T.; Shinohara, N.; Nonomura, N.; Ozono, S.; Eto, M.; Tatsugami, K.; Takayama, T.; Matsuyama, H.; Kishida, T.; Oya, M. 2019: Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma Cancer Science 110(6): 1820-1828
Yu, W-Bo.; Rao, J-Yu. 2019: Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma Chronic Diseases and Translational Medicine 5(3): 170-177
Bernard-Tessier, A.; Baldini, C.; Martin, P.; Champiat, Séphane.; Hollebecque, A.; Postel-Vinay, S.; Varga, A.; Bahleda, R.; Gazzah, A.; Michot, J-Marie.; Ribrag, V.; Armand, J-Pierre.; Marabelle, Aélien.; Soria, J-Charles.; Massard, C. 2018: Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression European Journal of Cancer 101: 160-164
Zhou, T.; Xu, D.; Tang, B.; Ren, Y.; Han, Y.; Liang, G.; Wang, J.; Wang, L. 2018: Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis Anti-Cancer Drugs 29(9): 904-910
Wang, S.; Hu, C.; Xie, F.; Liu, Y. 2020: Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer Oncotargets and Therapy 13: 667-683
Guan, J.; Lim, K.Sandar.; Mekhail, T.; Chang, C-Che. 2017: Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers Archives of Pathology and Laboratory Medicine 141(6): 851-861
Tominaga, T.; Akiyoshi, T.; Yamamoto, N.; Taguchi, S.; Mori, S.; Nagasaki, T.; Fukunaga, Y.; Ueno, M. 2019: Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Plos one 14(2): E0212978